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•	 High Incidence of 
Somatic BAP1 Alterations 
in Sporadic Malignant 
Mesothelioma
immunohistochemical (IHC) analyses to identify all 
possible genetic alterations of somatic BAP1 mutations 
in sporadic MMs. Of the 22 frozen MM biopsies from 
US MM patients, BAP1 mutation was found in 63.6% 
(n=14) using the combination of Sanger sequencing, 
Multiplex Ligation-Dependent Probe Amplification, 
copy number analysis and cDNA sequencing. No 
changes in methylation were detected in MMs, 
indicating that hypermethylation is not a significant 
mechanism for BAP1 inactivation in MM. Findings from 
IHC analysis supported those from genomic analyses, 
demonstrating normal nuclear BAP1 staining in 8 MM 
bearing wild-type BAP1 and absence of nuclear staining 
in 14 MM tumor cells bearing mutated BAP1. Validation 
of results in an independent cohort of 70 MM biopsies 
showed similar IHC results, with 67.1% showing loss 
of BAP1 nuclear staining, although materials were 
insufficient for molecular studies. No significant 
association was observed between BAP1 mutation 
frequency and gender, age of diagnosis, ethnicity, 
history of asbestos exposure or survival. To conclude, 
the findings suggest BAP1 as the most commonly 
mutated gene in MM, independent of ethnicity or other 
clinical parameters. Coupled to its presence in other 
malignancies, BAP1 could be a potential therapeutic 
target in MMs and many other cancers. IHC appeared 
to be the most accessible and reliable method to identify 
MM biopsies harboring BAP1 mutations. (p. 565)
The genetic alteration of nuclear deubiquitinase, BRCA-associated 
protein 1 (BAP1), has been shown to be a potential driver in 
malignant mesothelioma (MM). But there were significant 
differences in the reported incidence of somatic BAP1 mutations in 
MM across studies, which could be due to variations in ethnicities 
or methodologies employed. This study investigated and attempted 
to address these discrepancies via comprehensive genomic and 
•	 Dynamic Plasma EGFR 
Mutation Status as a 
Predictor of EGFR-TKI 
Efficacy in Patients with 
EGFR-Mutant Lung 
Adenocarcinoma
exon 19 deletions and 28 had an L858R mutation. 
Pretreatment plasma exhibited a sensitivity of 
59.7% and a specificity of 100% for EGFR mutation 
detection. A significantly higher sensitivity was found 
in stage IV-M1b patients versus stage IIIb and IV-M1a 
patients (78% versus 23.8%; P<0.001). Patients 
achieved an objective response rate of 74.2%, a disease 
control date (DCR) of 82.3%, 8.8 months of median 
progression-free survival (PFS), and 20.5 months of 
overall survival (OS). The independent predictor of 
lower DCR, shorter PFS, and shorter OS was failure 
to clear plasma EGFR mutations post-EGFR-TKI 
treatment (odds ratio 5.26, P=0.034; hazard ratio [HR] 
1.97, P=0.001; and HR 1.82, P=0.036, respectively). 
The authors concluded that the PNA-ZNA PCR clamp 
method is a robust method for evaluating changes 
in plasma EGFR mutation status, which could be 
an independent predictor of EGFR-TKI efficacy 
in patients, particularly those with more advanced 
disease. (p. 603)
Chang et al. assessed the predictive role of plasma cell-free 
DNA (cfDNA) EGFR mutation status in EGFR-tyrosine 
kinase inhibitor (TKI) treatment for 72 patients with advanced 
lung adenocarcinoma treated with first-line EGFR-TKI. This 
prospective study employed a peptide nucleic acid-Zip nucleic 
acid polymerase chain reaction (PNA-ZNA PCR) clamp method 
in matched tumor and serial plasma cfDNA samples. EGFR 
mutation was detected in 62 (86.1%) patients. Thirty-four had 
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•	 Final Overall Survival 
Results from a Phase III, 
Randomized, Placebo-
Controlled, Parallel-Group 
Study of Gefitinib Versus 
Placebo as Maintenance 
Therapy in Patients with 
Locally Advanced or 
Metastatic Non–Small-Cell 
Lung Cancer (INFORM; 
C-TONG 0804)
of lung tumors in all models. In all 3 conditional 
knockout models, multiple pulmonary tumors arising 
from the large bronchi with in situ carcinoma and NE 
cell hyperplasia were observed. Inter- and intra-tumor 
presence of SCLC and large-cell NE cell carcinoma 
combination in different proportions were found, as well 
as occasional adeno- or large-cell carcinomas. Also, 
mainly SCLC demonstrated extensive vascular and 
lymphatic invasion and metastases to the mediastinum 
and liver. In the Rb/p53/PTEN triple knockout model 
and in the constitutive SV40/T antigen model, there 
were non-small cell lung carcinoma-NE tumors arising 
peripherally, induced by specific genetic alterations, 
inactivation of one or both alleles of specific genes, 
time from Cre activation, and targeting lung cells or 
NE cell subpopulations. Taken together, the findings 
suggested that these 5 GEMM models represent one 
of the most advanced GEMM models for the whole 
spectrum of human high-grade NE carcinomas, valuable 
for investigation of the pathogenesis and metastatic 
characteristics of these tumors. (p. 553)
•	 The Comparative 
Pathology of Genetically 
Engineered Mouse Models 
for Neuroendocrine 
Carcinomas of the Lung
This study evaluated the pathologies of 5 genetically-engineered 
mouse models (GEMMs) for small-cell lung carcinomas (SCLC) 
and other high-grade lung neuroendocrine (NE) carcinomas, 
including the original Rb/p53 double knockout and triple knockouts 
(double knockout plus loss of p130 or loss of Pten), as well as a 
GEMM with a constitutive co-expression of SV40 large T antigen 
and Ascl1 under the Scgb1a1 promoter. Tissues from over 120 
mice were obtained for immunohistochemistry analysis. The 
results revealed both common and distinct pathological features 
This report demonstrated the results of a mature analysis 
comparing the overall survival (OS) of the gefitinib 
arm or the placebo arm in the maintenance setting 
for patients with advanced non-small cell lung cancer 
(NSCLC) in an intention to treat (ITT) population and 
in subgroups with different epidermal growth factor 
receptor (EGFR) mutation status. From the 296 patients 
randomized to gefitinib or placebo, the results showed 
no significant difference in OS between arms in the ITT 
population (hazard ratio [HR], 0.88; p = 0.335), and 
in wild-type EGFR (HR, 1.27; p = 0.431) or unknown 
EGFR status (HR, 0.92; p = 0.603) subgroups. A 
significantly improved OS was observed in the gefitinib 
arm in the EGFR mutation-positive subgroup (HR, 
0.39; p = 0.036). Overall, the findings demonstrated 
that patients with advanced NSCLC harboring an 
EGFR mutation had improved OS from gefitinib in the 
maintenance setting. (p. 655)
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the same histopathologic subtype and invasion extent 
by 3 thoracic pathologists based on the World Health 
Organization (WHO), Bernatz and proposed Suster and 
Moran (S&M) classifications (n=145, 120 and 214, 
respectively). With a median follow-up of 7.5–7.7 years 
(between classifications), overall survival (OS) and 
disease-free survival (DFS) were associated with all 
histopathologic classifications (p≤0.0001 to p=0.048). 
Only Bernatz classification was significant for OS when 
adjusted for modified Masaoka stage (p=0.04). Modified 
Masaoka stage predicted outcome regardless of all 
histopathologic classifications and resection status. It 
also significantly correlated with the proposed Moran 
stage (correlation coefficient, 0.95). Independent of any 
histopathologic classification, thymoma size and age 
were prognostic for OS. Taken together, histopathologic 
classifications of thymomas, although associated with 
prognosis, are not independent predictors of outcome. 
Instead, modified Masaoka staging and proposed Moran 
staging are superior to histopathologic classifications as 
independent prognostic predictors for thymoma. (p. 691)
•	 Modified Masaoka Stage 
and Size Are Independent 
Prognostic Predictors in 
Thymoma and Modified 
Masaoka Stage is Superior 
to Histopathologic 
Classifications
This study evaluated the prognostic value of histopathologic 
classifications of thymoma and compared the outcome to existing 
prognostic parameters. Resected thymoma samples were staged 
using modified Masaoka staging and Moran staging. Thymomas 
included in the outcome analysis were independently classified as 
RESEARCH WATCH
•	 Sputum microRNA 
Biomarkers for 
Identifying Lung Cancer 
in Indeterminate Solitary 
Pulmonary Nodules
To address unidentifiable solitary pulmonary nodule 
(SPN) detected by low-dose computed tomography 
(LDCT) in asymptomatic individuals, the authors 
developed and validated a panel of 3 sputum 
microRNAs (miRNAs) biomarkers for diagnosis of 
malignant SPNs. In a training set of 122 patient SPNs 
(60 malignant; 62 benign), previously identified sputum 
miRNA signatures of lung cancer (13 miRNAs) were 
evaluated and a panel of biomarkers were determined. 
The panel was then validated by internal (67 malignant 
and 69 benign SPNs) and external (76 malignant and 
79 benign SPNs) cohorts. In identifying malignant 
SPNs, the 3-miRNA (miRs 21, 31, and 210) panel 
demonstrated a sensitivity of 82.93% and a specificity 
of 87.84% in the training set, and 82.09% and 88.41%, 
80.52% and 86.08%, respectively, in the 2 independent 
validation cohorts. The findings suggested the 
diagnostic significance of sputum miRNA biomarkers 
for preoperative detection of malignant SPNs, which 
could potentially improve LDCT screening in lung 
cancer. Further studies will include new technologies to 
discover and expand sputum miRNA biomarker panel, 
leading to a test with improved specificity for early 
detection of lung cancer in clinical settings.
Xing L, Su J, Guarnera MA, et al. Sputum microRNA 
Biomarkers for Identifying Lung Cancer in 
Indeterminate Solitary Pulmonary Nodules. Clin Cancer 
Res 2015;21:484–489.
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6: 31.4 vs. 18.4 months; HR = 0.64; p = 0·023). In 
contrary, patients with tumors harboring Leu858Arg 
EGFR mutation did not show a significant difference 
in median OS in either arm in both trials (LUX-Lung 
3: 27.6 vs. 40.3 months; HR = 1.30; p = 0·29; LUX-
Lung 6: 19.6 vs. 24.3 months; HR = 1.22; p = 0·34). 
The most common grade 3–4 adverse events associated 
with afatinib were rash or acne (16% in LUX-Lung 
3; 15% in LUX-Lung 6) and diarrhea (14% in LUX-
Lung 3; 5% in LUX-Lung 6). Grade 3–4 paronychia 
was observed in 11% of patients in LUX-Lung 3, and 
stomatitis or mucositis was found in 5% of patients in 
LUX-Lung 6. Taken together, afatinib did not improve 
OS of the overall population in both trials, but it did 
significantly improve the OS of patients harboring del19 
EGFR mutations. The lack of similar survival benefits 
in the Leu858Arg EGFR mutation-positive population 
indicated that standard treatments should no longer be 
given to these different subgroups, and that separate 
analysis and approaches are warranted in future studies.
Yang JC-H, Wu Y-L, Schuler M, et al. Afatinib 
versus cisplatin-based chemotherapy for EGFR 
mutation-positive lung adenocarcinoma (LUX-Lung 3 
and LUX-Lung 6): analysis of overall survival data from 
two randomised, phase 3 trials. The Lancet Oncology 
2015;16:141–151.
•	 Clinical Experience with 
Crizotinib in Patients with 
Advanced ALK-Rearranged 
Non–Small-Cell Lung 
Cancer and Brain 
Metastases
12 weeks, 56% intracranial DCR, and 7 months 
of median intracranial time to progression (TTP). 
The previously treated cohort demonstrated similar 
results: 65% systemic disease control rate (DCR) at 
12 weeks, 62% intracranial DCR, and 13.2 months 
of median intracranial time to progression (TTP). 
Systemic disease control was also associated with 
intracranial disease control at 12 weeks (correlation 
coefficient, 0.7652; P < 0.001). The study also found 
20% diagnosed with brain metastases in the cohort 
of patients without baseline brain metastases but 
with progressive disease after treated with crizotinib 
(n=253). To conclude, the findings of this study 
demonstrated the association of crizotinib treatment 
with >55% CNS disease control at 12 weeks, which 
was comparable to the systemic rate. However, 
acquired resistance to crizotinib leading to disease 
progression dominantly in the CNS warrants further 
investigation into the mechanism to help guide 
crizotinib treatment in this setting.
Costa DB, Shaw AT, Ou SH, et al. Clinical 
experience with crizotinib in patients with advanced 
ALK-rearranged non-small-cell lung cancer 
and brain metastases. J Clin Oncol doi:10.1200/
jco.2014.59.0539 (2015).
•	 Afatinib versus Cisplatin-
Based Chemotherapy for 
EGFR Mutation-Positive 
Lung Adenocarcinoma 
(LUX-Lung 3 and LUX-Lung 
6): Analysis of Overall 
Survival Data from Two 
Randomised, Phase 3 Trials
This study evaluated the overall survival (OS) of previously 
untreated patients with EGFR mutation-positive stage IIIB or IV 
lung adenocarcinoma treated with afatinib versus cisplatin-based 
chemotherapy using data from LUX-Lung 3 (n=345) and LUX-
Lung 6 (n=364). Median follow-up was 41 months in LUX-Lung 
3 and 33 months in LUX-Lung 6. In the overall population, no 
significant difference in median OS was observed between the 
afatinib arm and the chemotherapy arm in LUX-Lung 3 (28.2 vs. 
28.2 months; hazard ratio [HR] = 0.88; p = 0·39) and LUX-Lung 6 
(23.1 vs. 23.5 months; HR = 0.93; p = 0·61). In patients with tumors 
harboring exon 19 deletion (del19), afatinib significantly prolonged 
median OS compared to that in chemotherapy in both trials (LUX-
Lung 3: 33.3 vs. 21.1 months; HR = 0.54; p = 0·0015; LUX-Lung 
This retrospective study assessed the clinical benefits of crizotinib 
in patients with advanced ALK-positive non-small cell lung cancer 
(NSCLC) with brain metastases from the PROFILE 1005 or 1007 
trial. Of 888 patients evaluated, 31% had baseline asymptomatic 
brain metastases, in which 109 were untreated and 166 were 
treated with prior brain radiotherapy. The previously untreated 
cohort showed a 63% systemic disease control rate (DCR) at 
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at 1 month, was 40% in the cytisine arm and 31% in the 
nicotine arm. Cytisine showed superior effectiveness 
for continuous abstinence over nicotine at 1 week, 2 
months, and 6 months. Cytisine was superior to nicotine 
in women and noninferior in men. Self-reported adverse 
events, mainly nausea, vomiting and sleep disorders, 
were more frequent in the cytisine group and the 
nicotine group. This study demonstrated that cytisine 
was superior to nicotine-replacement therapy in helping 
smoking cessation in conjunction with behavioral 
support, with more self-reported adverse events.
Walker N, Howe C, Glover M, et al. Cytisine 
versus nicotine for smoking cessation. NEJM 
2014;371:2353–2362.
•	 Electronic Nicotine 
Delivery Systems: A 
Policy Statement from 
the American Association 
for Cancer Research and 
the American Society of 
Clinical Oncology
patterns of usage, and their roles in smoking cessation. 
The organizations convened an expert panel consisting 
of the Tobacco and Cancer Subcommittee of the AACR 
Science Policy and Government Affairs Committee and 
ASCO Tobacco Cessation and Control Subcommittee 
of the Cancer Prevention Committee to develop a 
joint policy statement. The statement recommends key 
policy changes, including ENDS regulation at federal, 
state, and local levels; mandate manufacturers to 
comply with the FDA rules on product warning labels, 
reporting all product ingredients and having childproof 
caps on ENDS liquid; bans on ENDS use where 
cigarette smoking is banned, on ENDS flavors that 
appeal to children, and on marketing and sales  
targeting youth.
Brandon TH, Goniewicz ML, Hanna NH, et al. 
Electronic nicotine delivery systems: A policy statement 
from the American Association for Cancer Research 
and the American Society of Clinical Oncology. J Clin 
Oncol doi:10.1200/jco.2014.59.4465 (2015).
•	 Cytisine versus Nicotine 
for Smoking Cessation
Since cytisine, a partial agonist for the nicotinic acetylene receptor, 
has been shown to be very effective in promoting smoking cessation, 
the authors sought to compare its efficacy with that of nicotine-
replacement therapy in helping smokers quit in an open-label, 
noninferiority trial in New Zealand. Adult daily smokers (n=1310) 
who called the national quitline were randomized to cytisine for 25 
days (received free by mail) or nicotine-replacement therapy for 8 
weeks (received through vouchers for low-cost patches with gum 
or lozenges). Both groups also received behavioral support via the 
quitline. The primary outcome, self-reported continuous abstinence 
Electronic nicotine delivery systems (ENDS) are battery-operated 
devices delivering nicotine vapor instead of combusting tobacco, 
and being marketed as a substitute for tobacco smoking, with 
claims of harm-reduction and smoking cessation interventions. The 
good and bad of ENDS depend on if the use of ENDS results in 
reduced rates of smoking and known adverse effects of smoking, 
or increased possibility of nonsmokers and former smokers to use 
tobacco products, especially in youth, and discouraging smokers 
from quitting, respectively. Acknowledging the impact of ENDS 
on tobacco use and public health and the limited data on long-term 
health consequence of ENDS, the American Association for Cancer 
Research (AACR) and the American Society of Clinical Oncology 
(ASCO) recommend further studies on ENDS on health impacts, 
NEWS IN BRIEF
•	 MPDL3280A Gets FDA 
Breakthrough Therapy 
Designation for Non–Small 
Cell Lung Cancer
MPDL3280A, an anti-PD-L1 monoclonal antibody, 
has been granted Breakthrough Therapy designation 
by the FDA for the treatment of patients with PD-L1-
positive non-small cell lung cancer (NSCLC), which has 
progressed on or after platinum-based chemotherapy, 
and a targeted therapy for the EGFR mutant or ALK-
positive tumors. The designation is based on early stage 
data of the immunotherapy in patients with NSCLC 
expressing PD-L1, as detected by a Roche investigational 
diagnostic. The findings showed an objective response 
rate of 23% in the study patient population, and a 
24-week progression-free survival rate of 44% in 
squamous cell NSCLC and 46% in nonsquamous 
NSCLC. Adverse events were predominantly mild, 
without grade 3 to 5 pneumonitis or diarrhea.
Image credit: Yale Rosen | Wikimedia Commons | 
CC-BY-SA-2.0
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The FDA has granted Orphan Drug designation to 
Tarextumab, a human monoclonal antibody that targets 
Notch 2/3 receptors, for the treatment of small cell 
lung cancer (SCLC) and pancreatic cancer. Tarextumab 
was evaluated in combination with platinum-based 
chemotherapy and etoposide in patients with untreated 
extensive-stage SCLC in a phase Ib/II trial, PINNACLE. 
The analysis of 16 patients showed 81.3% with partial 
response and 18.8% with stable disease. Final survival 
and safety data from the phase Ib of the study will be 
presented this year at a meeting.
NEWS FROM THE  
IASLC TOBACCO  
CONTROL COMMITTEE
•	 More from Big Bully
tribunal (UNCITRAL, United Nations Commission on 
International Trade Law) on 14 April 2014. This was a 
bit of a win for the Australian government with success 
in the “argument for bifurcation”. What is that? Well, 
the attempts by Philip Morris to block plain packaging 
legislation in Australia (under ISDS provisions within 
a bilateral investment treaty signed between Australia 
and Hong Kong in the 1990s) are building up, layer 
by layer, over time. At some point (in October 2013) 
Australia argued for a “bifurcation” of the proceedings, 
a division of the arguments into two blocks. This is 
nicely explained by the McCabe Centre for Law and 
Cancer (http://www.mccabecentre.org/focus-areas/
tobacco/philip-morris-asia-challenge) and can be 
summarized as a request to divide the proceedings into 
(1) procedural objections and (2) objections based on 
merits of the claim. The procedural objections (of the 
Australian government against PMA’s claim) are to 
do with PMA investment in PM Australia, that PMA’s 
claim falls outside the scope of the treaty and that shares 
owned in PML (Philip Morris Limited – a subsidiary 
of PM Australia) do not constitute “investments” for 
the purposes of the treaty. Australia won this point 
(to bifurcate the proceedings and therefore argue the 
procedural stuff separately) and therefore has a chance 
to have the whole thing thrown out because the PMA 
claim may become irrelevant under the treaty. The next 
phase of all this was set down for a start date on 16 
February 2015, when the tribunal (UNCITRAL) will 
consider the procedural points and decided whether or 
not anything can go further. And Philip Morris gets to 
drag it on longer and longer and longer. The Big Bully.
•	 FDA Grants Tarextumab 
Orphan Drug Designation 
for Lung and Pancreatic 
Cancers
Image source: NCI
Philip Morris is at it again. Readers may remember from this 
column in June and October 2014 that various subsidiaries of Philip 
Morris are using the complexities of trade agreements and Investor-
State Dispute Settlement provisions (ISDS) provisions against 
tobacco control moves in countries such as Australia. As a reminder, 
ISDS provisions in trade agreements aim to protect companies from 
poor decisions made by the countries in which they invest. Philip 
Morris has in past used ISDS provisions to challenge the Australian 
government on health warnings and lost. Now they are trying 
again, this time to block plain packaging. The Australian Attorney-
General’s Department has a very informative (and freely accessible) 
website (www.ag.gov.au) which has most of the details. The latest 
in a long line of moves by Philip Morris comes with a challenge 
from Philip Morris Asia (PMA) against the Australian tobacco 
plain packaging legislation passed into law on 1 December 2011. 
This has all been going on for many years, since the Procedural 
Order No. 1 (7 June 2012) through to Procedural Orders Nos. 9 
and 10 (12 January 2015). What are these you say? It is hard for 
non-lawyers to get all of this and much of it is not publicly available 
but we can get a clue from Procedural Order No. 8, issued by the 
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•	 Online Anti-Tobacco News http://www.bbc.co.uk/news/health-31439273
This month we have two links to audiovisual presentations online. 
The first is a BBC interactive video which discusses smoking bans 
in the UK and links to archival footage from early anti-tobacco 
advertising. The second is a link to the UCSF “It’s about a Billion 
Lives” Symposium 2015, a wide-ranging look at the various ways 
that tobacco companies infiltrate the modern consciousness and the 




“JEFF WE CAN” – The Marlboro Man for the 
Modern Times
And don’t miss this, from “Last Week Tonight” 
hosted by John Oliver. A wonderful, entertaining and 
very sobering review of the tobacco industry’s behavior 
in the face of tobacco control efforts around the 
world. If you missed it, you can check out the show in 
YouTube:
https://www.youtube.com/watch?v=6UsHHOCH4q8
